medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 3

<< Back Next >>

Ann Hepatol 2015; 14 (3)

Serum ferritin is a biomarker for liver mortality in the Hemochromatosis and Iron Overload Screening Study

Adams PC, Barton JC, Guo H, Alter D, Speechley M

Language: English
References: 26
Page: 348-353
PDF size: 137.92 Kb.


ABSTRACT

Background. We identified no reports of long-term follow-up of participants in hemochromatosis screening programs. We evaluated causes of death and survival in non-C282Y homozygous Canadian participants in the primary care-based hemochromatosis and iron overload screening (HEIRS) study. Material and methods. Initial screening (IS) included transferrin saturation (TS), serum ferritin (SF), HFE genotyping (C282Y, H63D), and health questionnaire responses. By definition, participants without C282Y or H63D had HFE wt/wt. We linked 20,306 Canadian participants to the Ontario Death Registry for dates and causes of death 9 y after IS. We computed Cox proportional hazards to identify factors with increased death risks and Kaplan-Meier curves to estimate survival of non-C282Y homozygous participants with SF ≤ 1,000 µg/L and › 1,000 µg/dL. Results. There were 19,052 evaluable participants (IS mean age 49 y; 60% women; 93 C282Y homozygotes). There were 988 deaths. Significantly increased hazard ratios for all-cause mortality were positively associated with TS, SF, men, and C282Y homozygosity, and liver disease, diabetes, and heart failure reports. Non-C282Y homozygous participants with SF › 1,000 µg/L had lower survival than those with SF ≤ 1,000 µg/L (p ‹ 0.0001). Conclusions. Nine years after initial screening, non-C282Y homozygous participants and SF ‹ 1,000 µg/L was associated with decreased survival.


REFERENCES

  1. Camaschella C, Poggiali E. Towards explaining “unexplained hyperferritinemia”. Haematologica 2009; 94: 307-9.

  2. Kannengiesser C, Jouanolle AM, Hetet G, Mosser A, Muzeau F, Henry D, Bardou-Jacquet E, et al. A new missense mutation in the L ferritin coding sequence associated with elevated levels of glycosylated ferritin in serum and absence of iron overload. Haematologica 2009; 94: 335-39.

  3. Adams PC, Reboussin DM, Barton JC, McLaren CE, Eckfeldt JH, McLaren GD, Dawkins FW, et al. Hemochromatosis and Iron-Overload Screening in a Racially Diverse Population. N Engl J Med 2005; 352: 1769-78.

  4. McLaren CE, Barton JC, Adams PC, Harris E, Acton R, Press N, Reboussin DM, et al. Hemochromatosis and Iron Overload Screening (HEIRS) Study Design for an Evaluation of 100,000 Primary Care-Based Adults. Am J Med Sci 2003; 325: 53-62.

  5. Gordeuk VR, Reboussin DM, McLaren CE, Barton JC, Acton RT, McLaren GD, Harris EL, et al. Serum ferritin concentrations and body iron stores in a multicenter, multiethnic primary-care population. Am J Hematol 2008; 83: 618-26.

  6. Adams PC, Passmore L, Chakrabarti S, Reboussin D, Acton R, Barton J, McLaren GD, et al. Liver diseases in the Hemochromatosis and Iron Overload Screening Study. Clin Gastroenterol Hepatol 2006; 4: 918-23.

  7. Pankow JS, Boerwinkle E, Adams PC, Guallar E, Leiendecker- Foster C, Rogowski J, Eckfeldt J. HFE C282Y homozygotes have reduced low-density lipoprotein cholesterol: the Atherosclerosis Risk in Communities (ARIC) Study. Translational Research 2008; 152: 3-10.

  8. Powell L, Dixon J, Ramm G, Purdie DM, Lincoln D, Anderson G, Subramaniam N, et al. Screening for hemochromatosis in asymptomatic subjects with and without a family history. Arch Int Med 2006; 166: 294-301.

  9. Falize L, Guillygomarch A, Perrin M, Laine F, Guyader D, Brissot P, Turlin B, et al. Reversibility of hepatic fibrosis in treated genetic hemochromatosis: a study of 36 cases. Hepatology 2006; 44: 472-7.

  10. Zacharski LR, Shamayeva G, Chow BK. Effect of controlled reduction of body iron stores on clinical outcomes in peripheral arterial disease. Am Heart J 2011; 162: 949-57.

  11. Beaton M, Chakrabarti S, Levstik M, Speechley M, Marotta P, Adams P. Phase II Clinical Trial of phlebotomy therapy for non-alcoholic liver disease. Aliment Pharmacol Ther 2013: 37: 720-9.

  12. Valenti L, Fracanzani AL, Dongiovanni P, Bugianesi E, Marchesini G, Manzini P, Vanni E, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol 2007; 102: 1251-8.

  13. Houschyar KS, Ludtke R, Dobos GJ, Kalus U, Broecker- Preuss M, Rampp T, Brinkhaus B, et al. Effects of phlebotomy- induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial. BMC Med 2012; 10: 54.

  14. Bofill C, Joven J, Bages J, Vilella E, Sans T, Cavalle P, Miralles R, et al. Response to repeated phlebotomies in patients with non-insulin-dependent diabetes mellitus. Metabolism 1994; 43: 614-20.

  15. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and betacell function. Diabetes 2002; 51: 1000-04.

  16. Zacho J, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein and all-cause mortality—the Copenhagen City Heart Study. Eur Heart J 2010; 31: 1624-32.

  17. Maiwall R, Kumar S, Chaudhary AK, Maras J, Wani Z, Kumar C, Rastogi A, et al. Serum ferritin predicts early mortality in patients with decompensated cirrhosis. J Hepatol 2014; 61: 43-50.

  18. Walker NM, Stuart KA, Ryan RJ, Desai S, Saab S, Nicol JA, Fletcher LM, et al. Serum ferritin concentration predicts mortality in patients awaiting liver transplantation. Hepatology 2010; 51: 1683-91.

  19. Al-Freah MA, Kriese S, Foxton MR, Quaglia A, Bomford A, Heaton ND, O’Grady JG, et al. The association of pretransplant ferritin level with waiting list and post-transplant survival. Does ferritin actually predict outcome? Transpl Int 2013; 26: 1070-9.

  20. Barton JC, Lafreniere SA, Leiendecker-Foster C, Li H, Acton RT, Press RD, Eckfeldt JH. HFE, SLC40A1, HAMP, HJV, TFR2, and FTL mutations detected by denaturing high-performance liquid chromatography after iron phenotyping and HFE C282Y and H63D genotyping in 353 Ferritin and mortality. , 2015; 14 (3): 348-353 785 HEIRS Study participants. Am J Hematol 2009; 84: 710-4.

  21. Cook JD, Finch CA, Smith NJ. Evaluation of the iron status of a population. Blood 1976; 48: 449-55.

  22. Barton J, Acton R, Dawkins F, Adams P, Lovato L, Leiendecker- Foster C, McLaren CE, et al. Initial screening transferrin saturation values, serum ferritin concentrations, and HFE genotypes in whites and blacks in the hemochromatosis and iron overload screening study. Genet Test 2005; 9: 231-41.

  23. Harris EL, McLaren CE, Reboussin DM, Gordeuk VR, Barton JC, Acton RT, McLaren GD, et al. Serum ferritin and transferrin saturation in Asians and Pacific Islanders. Arch Intern Med 2007; 167: 722-6.

  24. Ellervik C, Marott JL, Tybjaerg-Hansen A, Schnohr P, Nordestgaard BG. Total and Cause-Specific Mortality by Moderately and Markedly Increased Ferritin Concentrations: General Population Study and Meta-analysis. Clin Chem 2014; 60: 1419-28.

  25. Stack A, Mutwali A, Nguyen H, Cronin C, Casserly L, Ferguson J. Transferrin saturation ratio and risk of total and cardiovascular mortality in the general population. QJM 2014; 107: 623-33.

  26. Menke A, Muntner P, Fernandez-Real JM, Guallar E. The association of biomarkers of iron status with mortality in US adults. Nutr Metab Cardiovasc Dis 2012; 22: 734-40.




2020     |     www.medigraphic.com